TNF and rheumatoid arthritis: Therapeutic blockade of TNFα with neutralizing antibodies (e.g., infliximab) or soluble TNFα receptor immunoglobulin constructs (e.g., etanercept) has been the gateway for the biologic DMARD in the treatment of RA.